Spotlight

Ambulatory Pathway for Oncology Patients with Low Risk Febrile Neutropenia

Update of the Ambulatory Pathway for Oncology Patients with Low Risk Febrile Neutropenia (LRFN). We are hoping to review and update the consensus pathway document for the ambulatory management of LRFN. We will be recruiting to a review group soon. In the meantime, we would like to collect some information about the implementation of LRFN pathways.

Would you please follow this link to complete a short questionnaire
We would like to receive any other LRFN pathway documents, guidelines, audit data, feedback that you have. Please send information to us using our contact page.

« Return to Spotlight

Ambulatory Pathway for Oncology Patients with Low Risk Febrile Neutropenia

The UK Acute Oncology Society (UKAOS) is most grateful to Exact Sciences and Pfizer for their joint funding support of the Society in its inaugural year; the support from Pfizer was in the form of an unrestricted educational grant. The companies have had no influence on the set up of UKAOS.